Clinical trial NCT01831141: Long Term Outcome of Congenital Solitary Kidney
Official title: Renal Outcome in Children With Congenital Solitary Kidney: a Longitudinal Prognostic Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Congenital Solitary Kidney
Keywords: Congenital Solitary Kidney
Glomerular filtration rate
Chronic kidney damage
Hypertension
Proteinuria
Lead sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Sponsor class: OTHER
First posted: 2013-04-15
Enrollment: 120
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children aged 0 - 18 years, diagnosed with a CSK (defined as a single functioning kidney documented and confirmed by DMSA Scan.).

Subjects will be enrolled from 1st June 2010 to 30th Jume 2013 at the Paediatric Nephrology Department of the Sant'Orsola Malpighi Hospital, the follow-up of each subject will continue for 10 years.

Brief summary: Congenital solitary kidney (CSK) is a disorder caused by an abnormal development of one of the two kidneys. The reported incidence ranges between 1:450-3200. It is debated whether CSK is a benign condition or not. A variable risk of developing proteinuria (11-27%), hypertension (0-60%) and chronic kidney damage (3.5-30%) is described. This knowledge derives mainly from retrospective studies performed in tertiary medical centers which is difficult to compare for the following reasons: the number of individuals evaluated, the length of follow-up and the outcome studied.

The aim of this longitudinal study is to assess, in a cohort of children with congenital solitary kidney, during a 10 year follow-up period: 1) the rates of developing proteinuria, hypertension and chronic kidney disease and the corresponding potential prognostic factors. 2) the role of new biomarkers of glomerular (Cystatin C) or tubular damage (NGAL, NAG, B2-microglobulin) in predicting the appearance of chronic kidney damage.

Detailed description: Congenital Solitary kidney (CSK) is a disorder caused by the abnormal development of one of the two kidneys. This abnormality can be either anatomical, caused by unilateral renal agenesis (RAG), or functional, caused by extreme forms of dysplasia (renal aplasia-RAP and multicystic dysplastic kidney disease-MCKD). The reported incidence is between 1:450-3200 with no difference between the two sexes. CSK is a subgroup of a large family of Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), which are caused by abnormal embryologic development. Physiologically, the development of the kidney begins during the 3rd week of gestation and proceeds through a series of phases: the pronephros, mesonephros, and metanephros. While abnormalities of the early pronephros-mesonephros phases lead to renal agenesis, an aberrant metanephros phase can cause a more wide spectrum of CAKUT. CAKUT are the leading cause of chronic (50%) and end stage (40%) kidney disease in children. While this risk is well known for some phenotypes (e.g. bilateral renal hypodysplasia and posterior urethral valves), whether CSK is a benign condition or not, has been the subject of recent debate. The knowledge of the natural history of CSK originates mainly from retrospective studies often performed in tertiary medical centers which are difficult to compare for several reasons: the number of individuals studied varied considerably as did the underlying CSK disorders (RAG, MCKD or RAP), the length of follow-up and the type of outcomes considered. These studies show an extremely variable risk of developing proteinuria (11-27%), hypertension (0-60%), and chronic kidneys disease (3.5-30%). So there are many difficulties which prevent us from understanding: a) which phenotype (RAG, MCKD or RAP) or risk factors could influence the progression to an adverse outcome; b) whether or not the compensatory hypertrophy and resulting hyperfiltration acts as a protective mechanism. Recently, Sanna-Cherchi et al. retrospectively analyzed the long-term renal outcome of over 300 children with CAKUTs. With simple selection criteria, dialysis-free survival from birth was modelled to account for concomitant vesicoureteral reflux, age at diagnosis, hypertension, proteinuria, and serum creatinine concentration. Surprisingly the analysis revealed that patients with solitary kidney have a probability of nearly 50 % of requiring dialysis by 30 years of age. This clinical outcome raises the possibility that subclinical defects could be present in the congenital solitary kidney which may account for a poorer prognosis. This hypothesis is also supported by the fact that the long-term prognosis in individuals with acquired single kidney (e.g. transplant donors or subject nephrectomized for Wilm's tumor) appears to be excellent. This reported high risk of poor outcome in CSK patients has highlighted the need for understanding: 1) the rate and the factors determining progression to end-stage renal disease; 2) the development of biomarkers to improve early detection. Usually, children with CSK are not always subjected to long term follow-up and when they are, monitoring involves plasma creatinine concentration , proteinuria and ultrasonography. Because most cases of endstage renal disease in children result from tubulointerstitial rather than glomerular disorders, serum creatinine and urine protein determinations are relatively insensitive. New biomarkers are now available that can facilitate the early identification of changes in renal function before they become irreversible. These biomarkers of glomerular (serum Cystatin C) or tubular damage (urine alfa-1 and beta-2 microglobulin, urine lysozyme, serum and urine neutrophil gelatinase associated lipocalin (NGAL), urine Na+/H+ exchanger (NHE3), urine Kidney injury molecule 1 (KIM1), urine N-acetyl-beta-D-glucosaminidase (NAG), already validated for various kidney diseases (acute renal failure, nephrotic syndrome, etc), could be useful in the early identification of damage in CSK patients.

The aim of this longitudinal study is to assess, in a cohort of children with CSK, during a 10-year follow-up period:

1. the rates of developing proteinuria, hypertension and chronic kidney disease and potential prognostic factors.
2. the role of new biomarkers of glomerular or tubular damage in predicting the appearance of chronic kidney damage.

Study population:

Study group: male and female children, aged 0-18 years, diagnosed with CSK, documented by renal ultrasonography and confirmed by dimercaptosuccinic acid (DMSA) Scan. Written informed consent will be obtained. Children with chronic renal failure, posterior urethral valves, diabetes, heart and/or vascular diseases and autoimmune diseases will be excluded. Subjects will be enrolled at the Paediatric Nephrology Department of the Sant'Orsola Malpighi Hospital, Bologna, as in and/or outpatients from the 1st April 2010 to 30th April 2013; the follow-up of each subject will continue for 10 years.

At the baseline all children will be assess by:

1. Medical history;
2. Physical examination (anthropometric and blood pressure measurements);
3. Kidney and urinary tract ultrasonography (US);
4. Voiding cystourethrography (VCUG);
5. Clinical laboratory assessments: complete blood count, serum electrolyte, serum creatinine, serum urea, serum cystatin C, urine analysis, urine creatinine, microalbuminuria, urine electrolyte, urine α1-microglobulin, urine β2-microglobulin, urine lysozyme, serum and urine NGAL, urine NHE3, urine KIM1, urine NAG;
6. 99-technetium diethylene triamine pentaacetic acid scintigraphy (DTPA)(DTPA scan) in children aged more than 2 years.

Patient follow-up and monitoring:

1. Clinical examination with height, weight, BMI, blood pressure every six months in children up to 2 years and every year in children aged more than 3 years;
2. Biochemistry (every six months in children up to 2 years and every year in children aged more than 3 years): complete blood count, serum electrolyte, serum creatinine, serum urea, serum cystatin C, urine analysis, urine creatinine, microalbuminuria, urine electrolyte, urine α1-microglobulin, urine β2-microglobulin, urine lysozyme, serum and urine NGAL, urine NHE3, urine KIM1, urine NAG;
3. Kidney and urinary tract US with evaluation of renal length (every six months in children up to 2 years and every year in children aged more than 3 years);
4. DTPA scan:

If age ≤ 2 years: at 2 , 5 and 10 ten years; If age \> 2 years: at entry and then every five years; 5. Ambulatory blood pressure measurement: If age ≤ 7 years: at 7 years, 10 years and at the end of follow-up; If age \> 7 years at entry and then every five years.

The following epidemiological, clinical and laboratory data will be collected:

Epidemiological data:

* Sex;
* Age at diagnosis;
* Ethnicity;
* History.

Clinical data:

* Height, weight and BMI at each visit,
* Blood pressure measurement at each visit.

Laboratory data:

• Complete blood count, serum electrolyte, serum creatinine, serum urea, serum cystatin C, urine analysis, urine creatinine, microalbuminuria, urine electrolyte, urine α1-microglobulin, urine β2-microglobulin, urine lysozyme, serum and urine NGAL, urine NHE3, urine KIM1, urine NAG at each visit.

Instrumental data:

* US renal length at each visit;
* Glomerular filtration rate evaluated by DTPA scan;
* Ambulatory blood pressure meas

Eligibility criteria: Inclusion Criteria:

1. Age 0 to 18 years
2. Congenital Solitary Kidney
3. Male and female sex
4. Written Informed consent will be obtained

Children with chronic renal failure, posterior urethral valves, diabetes, heart and/or vascular diseases and autoimmune diseases will be excluded. Subjects will be enrolled at the

Exclusion Criteria:

1. Age \> 18 years
2. Chronic renal failure
3. Posterior urethral valves
4. Diabetes
5. Heart and/or vascular diseases
6. Autoimmune diseases

Primary outcomes:
measure: Chronic kidney disease
timeFrame: 10 years
Secondary outcomes:
measure: Proteinuria
timeFrame: 10 years
measure: Hypertension
timeFrame: 10 years
Other outcomes:
Locations:
city: Bologna
country: Italy
facility: Azienda Ospedaliero-Universitaria Sant'Orsola Malpighi,
state: Emilia Romagna
Study officials:
affiliation: Azienda Ospedaliero-Universitaria Sant'Orsola Malpighi, Bologna, Italy
name: Giovanni Montini, MD
role: STUDY_CHAIR
References: